Existing guidelines suggest that with careful clinical and biochemical follow-up, DA therapy may be tapered or discontinued after at least 2 years of treatment, if PRL concentration remains normal and there is no recurrent tumour on MRI5. This evidence concerns the gene PRL and neoplasm.